Another good news regarding the covaxin vaccine. The Lancet results from early clinical trials with no side effects with covaxin.
(Milcah Anila, Intern Journalist) Vijayawada: Another good news regarding the covaxin vaccine. The results of early clinical trials with no side effects with Covaxin were published in the Lancet Journal. The vaccine, which is based entirely on indigenous technology, was developed by the Indian Institute of Biotech, ICMR, and the National Institute of Virology.
However, there has been criticism of allowing the emergency use of the covaxin vaccine. Opposition groups called on the government to allow the vaccine to be used without completing the third phase of clinical trials.
However, Bharat Biotech has clarified that the vaccine is very safe. Volunteers who had been vaccinated explained that the vaccine had nothing to do with getting sick. Early clinical trials were successfully conducted in 11 hospitals across the country. Clinical trials were conducted on volunteers between the ages of 18-55.
The covaxin vaccine is called the BBV 152 vaccine. It has been reported that those who have been vaccinated have significantly increased immunity. If not, symptoms such as mild pain, headache, and fever at the site of vaccination were seen in a small number of volunteers. Now, the sector has jumped to the distribution of Covaxin vaccines in AP and Telangana.
More covaxin doses have reached Telangana. Reached Cold Storage at one crore from Bharat Biotech. Covaxin vaccine has already been given to health workers in the AP. Covaxin vaccine is being used in the second phase in Telangana. The sector has jumped to the distribution of the Covaxin vaccine in Telangana.
About Post Author
